theguardian.com
🌐 90% Global Worthiness
18-Year Remission Achieved in Neuroblastoma Patient via CAR T-cell Therapy
An 18-year remission in a neuroblastoma patient treated with CAR T-cell therapy, a pioneering immunotherapy involving genetically modified T-cells, showcases its potential for long-term remission in solid tumors, particularly for childhood cancers.
18-Year Remission Achieved in Neuroblastoma Patient via CAR T-cell Therapy
An 18-year remission in a neuroblastoma patient treated with CAR T-cell therapy, a pioneering immunotherapy involving genetically modified T-cells, showcases its potential for long-term remission in solid tumors, particularly for childhood cancers.
Progress
40% Bias Score
Good Health and Well-being